Plasminogen, human‐tvmh for the treatment of children and adults with plasminogen deficiency type 1
Haemophilia · 2023-11 · 29 (6) · 1556-1564
DOI: 10.1111/hae.14849 ↗Kurz gefasst
Fachartikel in der Zeitschrift Haemophilia, online erschienen am 06.09.2023. Verfasst von Amy D Shapiro und 5 weiteren Autor:innen. Beteiligte Einrichtung: Indiana Hemophilia and Thrombosis Center, Indianapolis, Indiana, USA. Hauptthemen laut MEDLINE: Plasminogen. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
Aim
An open‐label phase 2/3 study of plasminogen, human‐tvmh administered intravenously in paediatric and adult subjects with type 1 plasminogen deficiency was conducted. Interim data was previously reported. The final data on 15 subjects who completed the study up to a maximum of 124 weeks are reported here.
Methods
The primary objectives were to evaluate efficacy of plasminogen replacement therapy on clinically evident or visible lesions during 48 weeks of dosing and to achieve an increase in trough plasminogen activity levels by at least an absolute 10% above baseline during 12 weeks of treatment.
Results
The primary efficacy endpoint was achieved, as 100% of subjects ( n = 11) with visible and assessable non‐visible lesions at baseline demonstrated ≥ 50% improvement after 48 weeks of study drug treatment with plasminogen, human‐tvmh. All subjects achieved the targeted ≥ 10% increase in trough plasminogen activity above baseline through Week 12. Plasminogen, human‐tvmh at a dose of 6.6 mg/kg administered every 2–5 days for 48 weeks and every 1–7 days for up to 124 weeks was well tolerated.
Conclusion
This study provides additional evidence regarding the long‐term safety and clinical utility of replacement therapy with human plasminogen for the treatment of children and adults with type 1 plasminogen deficiency. Plasminogen, human‐tvmh received marketing approval on June 4, 2021. This trial was registered at www.clinicaltrials.gov as #NCT02690714.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Indiana Hemophilia and Thrombosis Center, Indianapolis, Indiana, USA.
- Prometic Biotherapeutics Inc, Rockville, Maryland, USA.
- Prometic Bioproduction, Laval, Quebec, Canada.
- Kedrion S.p.A, Castelvecchio Pascoli, Barga (LU), Italy.
- Department of Hematology, Oslo University Hospital and University of Oslo, Oslo, Norway.
ORCID-Profile: Amy D Shapiro, Karen Thibaudeau, Per Morten Sandset
Zitieren
APA
Shapiro, A. D., Nakar, C., Parker, J. M., Thibaudeau, K., Crea, R., & Sandset, P. M. (2023). Plasminogen, human‐tvmh for the treatment of children and adults with plasminogen deficiency type 1. Haemophilia, 29(6), 1556-1564. https://doi.org/10.1111/hae.14849
Vancouver
Shapiro AD, Nakar C, Parker JM, Thibaudeau K, Crea R, Sandset PM. Plasminogen, human‐tvmh for the treatment of children and adults with plasminogen deficiency type 1. Haemophilia. 2023;29(6):1556-1564. doi:10.1111/hae.14849
BibTeX
@article{Shapiro2023,
author = {Shapiro, Amy D and Nakar, Charles and Parker, Joseph M and Thibaudeau, Karen and Crea, Roberto and Sandset, Per Morten},
title = {Plasminogen, human‐tvmh for the treatment of children and adults with plasminogen deficiency type 1},
journal = {Haemophilia},
year = {2023},
volume = {29},
number = {6},
pages = {1556--1564},
doi = {10.1111/hae.14849}
}
EUVIMED